Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Apogee Therapeutics, Inc.NASDAQ: APGE
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares (diluted) growth accelerates
Q2 FY2026 weighted avg shares (diluted) of 75.44M shares rose 29.1% year over year, ahead of the +15.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 8.3% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.
Context
- Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +29.1% holds above the trailing-twelve-month pace of +15.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 60.69M USD
- Year-over-year change
- +10.0%
- 3-year CAGR
- +6.2%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.69M | +10.0% |
| FY2024 | 2024-12-31 | 55.19M | +9.0% |
| FY2023 | 2023-12-31 | 50.66M | -0.0% |
| FY2022 | 2022-12-31 | 50.67M | — |
Weighted Avg Shares (Diluted) vs competitors
How APGE compares with its peers on the latest reported figures
- APGE's LTM Jun 2026 weighted avg shares (diluted) of 66.14M shares is the 8th highest of the 10 companies compared; the peer median is 91.49M shares.
- Its year-over-year change of +15.7% is the 5th highest of 10, against a peer median of +15.3%.
- Over three fiscal years its annual growth of +6.2% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 189.27M | +2.9% | +5.0% | |
| LTM Mar 2026 | 139.28M | +13.5% | +13.3% | |
| LTM Jun 2026 | 110.81M | +34.8% | +125.3% | |
| LTM Mar 2026 | 99.68M | +6.6% | +12.1% | |
| LTM Sep 2026 | 91.49M | +16.1% | +9.4% | |
AAPGAscentage Pharma Group International | FY2025 | 89.03M | +17.9% | +75.5% |
| LTM Sep 2026 | 84.72M | +15.3% | +5.1% | |
| LTM Jun 2026 | 66.14M | +15.7% | +6.2% | |
| LTM Jun 2026 | 51.65M | +19.9% | +50.5% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | 37.84M | +13.4% | +223.8% |
| Peer median (excluding APGE) | 91.49M | +15.3% | +13.3% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.42M |
| Gross Profit | 0 | 0 | 0 | (1.42M) |
| Gross Margin | — | — | — | — |
| Research & Development | 27.79M | 68.42M | 167.87M | 214.71M |
| Selling, General & Admin | 2.94M | 24.58M | 49.01M | 70.88M |
| Operating Expenses | 30.73M | 93M | 216.87M | 284.18M |
| Depreciation & Amortization | 0 | 9.02M | 189K | 1.42M |
| EBITDA | (39.79M) | (74.97M) | (181.94M) | (254.15M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (30.73M) | (93M) | (216.87M) | (285.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 92K | 9.02M | 34.74M | 30.03M |
| Interest Expense | 9.15M | 0 | 0 | 0 |
| Other Income / Expenses | (9.06M) | 9.02M | 34.74M | 30.03M |
| Income Before Tax | (39.79M) | (83.99M) | (182.13M) | (255.57M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 18K | 278K |
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.79) | (1.66) | (3.30) | (4.22) |
| EPS (Diluted) | (0.79) | (1.66) | (3.30) | (4.22) |
| Weighted Avg Shares | 50.67M | 50.66M | 55.19M | 60.69M |
| Weighted Avg Shares (Diluted) | 50.67M | 50.66M | 55.19M | 60.69M |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.